

Frédéric Amant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5006330/publications.pdf>

Version: 2024-02-01

510
papers

28,703
citations

8181

76
h-index

8167

148
g-index

526
all docs

526
docs citations

526
times ranked

27966
citing authors

#	ARTICLE	IF	CITATIONS
1	TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	5.4	9
2	Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions. <i>Cancers</i> , 2022, 14, 1966.	3.7	14
3	Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 404-410.	4.7	12
4	Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 46-59.	2.8	18
5	Proton therapy of a pregnant patient with nasopharyngeal carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 33-36.	1.7	4
6	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. <i>European Journal of Cancer</i> , 2022, 170, 54-63.	2.8	13
7	Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the Effectiveness and quality of Endometrial Cancer Treatment (EFFECT). <i>BMC Cancer</i> , 2022, 22, .	2.6	1
8	Low-grade serous ovarian cancer in pregnancy. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 804-808.	2.5	1
9	Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands. <i>European Journal of Cancer</i> , 2022, 171, 13-21.	2.8	7
10	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
11	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
12	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	5.1	35
13	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188446.	7.4	41
14	AUTHOR REPLY. <i>Urology</i> , 2021, 151, 127-128.	1.0	0
15	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.	2.0	22
16	Renal and Bladder Cancer During Pregnancy: A Review of 47 Cases and Literature-based Recommendations for Management. <i>Urology</i> , 2021, 151, 118-128.	1.0	4
17	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021, 193, 52-62.	2.5	14
18	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 3176.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 1008.	3.7	25
20	Imaging modalities in pregnant cancer patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 423-431.	2.5	26
21	Management of pregnancy in women with cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 314-322.	2.5	47
22	Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. <i>Cancers</i> , 2021, 13, 1214.	3.7	11
23	Cervical cancer in pregnancy at various gestational ages. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 784-788.	2.5	4
24	Long-term neurodevelopmental outcome after prenatal exposure to maternal hematological malignancies with or without cytotoxic treatment. <i>Child Neuropsychology</i> , 2021, 27, 822-833.	1.3	4
25	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. <i>Cancers</i> , 2021, 13, 2040.	3.7	4
26	The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. <i>Cancer Research</i> , 2021, 81, 3876-3889.	0.9	21
27	Novel next-generation sequencing-based methodologies to characterize the mutational consequences of (prenatal) chemotherapy exposure in noncancerous tissue. <i>Current Opinion in Oncology</i> , 2021, 33, 476-484.	2.4	3
28	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	7.1	42
29	Incorporating molecular profiling into endometrial cancer management requires prospective studies. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 944-945.	2.5	10
30	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. <i>Lancet Oncology</i> , The, 2021, 22, 753-754.	10.7	57
31	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
32	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , 2021, 140, 1353-1365.	3.8	18
33	Wnt/ β -Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 705384.	2.8	17
34	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
35	Non-invasive prenatal testing suggesting a maternal malignancy: What do we tell the prospective parents in Belgium?. <i>Prenatal Diagnosis</i> , 2021, 41, 1264-1272.	2.3	20
36	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. <i>Cancers</i> , 2021, 13, 3988.	3.7	14

#	ARTICLE	IF	CITATIONS
37	Placental pathology in cancer during pregnancy and after cancer treatment exposure. <i>Placenta</i> , 2021, 111, 33-46.	1.5	6
38	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	2.8	7
39	Fertility sparing treatment in cervical cancer management in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 75, 101-112.	2.8	4
40	Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113562.	5.5	9
41	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31
42	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. <i>Data in Brief</i> , 2021, 38, 107354.	1.0	2
43	Cancer of the corpus uteri: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 45-60.	2.3	139
44	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. <i>Blood</i> , 2021, 138, 2457-2457.	1.4	0
45	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. <i>Cancers</i> , 2021, 13, 5848.	3.7	40
46	Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology</i> , The, 2021, 22, e550-e561.	10.7	37
47	Gynaecological Cancers and Pregnancy. , 2021, , 602-611.		0
48	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. <i>Acta Clinica Belgica</i> , 2020, 75, 9-18.	1.2	9
49	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 79-88.	2.8	18
50	Executive functioning in 6-year old children exposed to chemotherapy in utero. <i>Early Human Development</i> , 2020, 151, 105198.	1.8	7
51	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 538064.	2.8	9
52	Data describing child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. <i>Data in Brief</i> , 2020, 32, 106209.	1.0	4
53	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	3.2	9
54	Chemotherapy During Pregnancy: Careful Fetal Growth Monitoring Is Mandatory. <i>JCO Oncology Practice</i> , 2020, 16, 559-560.	2.9	5

#	ARTICLE	IF	CITATIONS
55	Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. <i>European Journal of Cancer</i> , 2020, 138, 57-67.	2.8	31
56	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. <i>Cancers</i> , 2020, 12, 3623.	3.7	10
57	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , 2020, 17, e1003111.	8.4	25
58	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	2.5	21
59	Pregnancy and Cancer: the INCIP Project. <i>Current Oncology Reports</i> , 2020, 22, 17.	4.0	72
60	Atypical Lesions of the Breast and Lobular Carcinoma in Situ in Pregnancy –“ Surgeons” Practice. <i>The Journal of Breast Health</i> , 2020, 16, 16-21.	1.0	1
61	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 417-431.	1.6	48
62	Surgical Principles of Endometrial Cancer. , 2020, , 153-174.		0
63	Management of Rare Uterine Malignant Tumors. , 2020, , 277-312.		0
64	Management and outcome of colorectal cancer during pregnancy: report of 41 cases. <i>Acta Chirurgica Belgica</i> , 2019, 119, 166-175.	0.4	28
65	Pregnant women with confirmed neoplasms should not have noninvasive prenatal testing. <i>Prenatal Diagnosis</i> , 2019, 39, 1162-1165.	2.3	17
66	FIGO 2018 stage IB2 (2–4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 969-975.	2.5	48
67	Long-term impact of prenatal exposure to chemotherapy on executive functioning: An ERP study. <i>Clinical Neurophysiology</i> , 2019, 130, 1655-1664.	1.5	3
68	Noninvasive Prenatal Testing and Detection of Occult Maternal Malignancies. <i>Clinical Chemistry</i> , 2019, 65, 1484-1486.	3.2	19
69	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2019, 6, e551-e561.	4.6	45
70	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1073.	2.8	28
71	Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. <i>Human Brain Mapping</i> , 2019, 40, 4994-5010.	3.6	25
72	Tamoxifen and pregnancy: an absolute contraindication?. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 17-25.	2.5	40

#	ARTICLE	IF	CITATIONS
73	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2019, 89, 90-98.	2.0	5
74	Influence of the corticospinal tract wiring pattern on sensorimotor functional connectivity and clinical correlates of upper limb function in unilateral cerebral palsy. <i>Scientific Reports</i> , 2019, 9, 8230.	3.3	19
75	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. <i>BMC Cancer</i> , 2019, 19, 506.	2.6	46
76	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , 2019, 120, 1037-1044.	6.4	10
77	Neoadjuvant Chemotherapy Followed by Surgery for Advanced-Stage Endometrial Cancer. <i>Current Oncology</i> , 2019, 26, 226-232.	2.2	30
78	Transplacental transport of paracetamol and its phase II metabolites using the ex vivo placenta perfusion model. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 14-23.	2.8	22
79	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 676-682.	2.5	35
80	Endometrial cancer during pregnancy: management strategies. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1221-1224.	2.5	2
81	Effects of in-utero exposure to chemotherapy on fetal brain growth. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1195-1202.	2.5	8
82	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2019, 79, 1646-1657.	0.9	31
83	Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. <i>Annals of Oncology</i> , 2019, 30, 85-95.	1.2	35
84	Development of Patient-Derived Tumor Xenograft Models. <i>Methods in Molecular Biology</i> , 2019, 1862, 217-225.	0.9	12
85	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 67-74.	1.0	22
86	Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 404-416.	2.5	21
87	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e86.	2.2	18
88	Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1304-1310.	2.5	1
89	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. <i>Reproductive Sciences</i> , 2018, 25, 1637-1648.	2.5	0
90	Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. <i>Case Reports in Oncology</i> , 2018, 11, 119-124.	0.7	22

#	ARTICLE	IF	CITATIONS
91	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	2.8	62
92	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. <i>Journal of Pathology</i> , 2018, 245, 283-296.	4.5	71
93	Genetic and microscopic assessment of the human chemotherapy-exposed placenta reveals possible pathways contributive to fetal growth restriction. <i>Placenta</i> , 2018, 64, 61-70.	1.5	21
94	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , The, 2018, 19, 337-346.	10.7	235
95	Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. <i>European Radiology</i> , 2018, 28, 1862-1874.	4.5	46
96	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 514-523.	2.5	43
97	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	5.5	46
98	Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues?. <i>BMC Cancer</i> , 2018, 18, 192.	2.6	15
99	Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?. <i>Brain Imaging and Behavior</i> , 2018, 12, 64-77.	2.1	52
100	Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 65-69.	1.6	5
101	A Real-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 156-163.	1.6	7
102	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	5.1	59
103	Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. <i>Laryngoscope</i> , 2018, 128, 1493-1500.	2.0	17
104	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 551-557.	2.5	33
105	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 37-50.	2.3	290
106	Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 620-626.	1.6	10
107	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. <i>Vaccines</i> , 2018, 6, 56.	4.4	7
108	Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1695-1703.	2.3	9

#	ARTICLE	IF	CITATIONS
109	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	12.8	178
110	Patient-Derived Xenograft Models for Endometrial Cancer Research. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2431.	4.1	32
111	Modeling Endometrial Cancer: Past, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2348.	4.1	82
112	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. <i>Frontiers in Nutrition</i> , 2018, 5, 138.	3.7	32
113	Association of a novel set of 7 homopolymer indels for detection of MSI with tumor mutation burden and total indel load in endometrial and colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15654-e15654.	1.6	2
114	Implementation of cancer treatment during pregnancy in daily practice: the important role of perinatologists. <i>Oncotarget</i> , 2018, 9, 31795-31796.	1.8	2
115	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
116	Sentinel-lymph-node mapping in endometrial cancer: routine practice?. <i>Lancet Oncology</i> , The, 2017, 18, 281-282.	10.7	17
117	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€”an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	7.0	30
118	Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. <i>Melanoma Research</i> , 2017, 27, 218-223.	1.2	16
119	Integration and validation of the ex vivo human placenta perfusion model. <i>Journal of Pharmacological and Toxicological Methods</i> , 2017, 88, 25-31.	0.7	34
120	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. <i>Development (Cambridge)</i> , 2017, 144, 1775-1786.	2.5	228
121	Cancer in pregnancy: safety and efficacy of systemic therapies. <i>Current Opinion in Oncology</i> , 2017, 29, 328-334.	2.4	23
122	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. <i>Gynecologic Oncology</i> , 2017, 146, 538-545.	1.4	16
123	Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage Iâ€”II Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1256-1260.	2.5	14
124	Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. <i>Journal of Pathology</i> , 2017, 242, 24-38.	4.5	54
125	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017, 77, e62-e66.	0.9	92
126	Effects of cancer treatment during pregnancy on fetal and child development. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 302-310.	5.6	48

#	ARTICLE	IF	CITATIONS
127	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7232-7241.	7.0	37
128	Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. <i>European Journal of Cancer</i> , 2017, 83, 88-98.	2.8	93
129	Low-grade bronchial mucoepidermoid carcinoma during pregnancy successfully treated by lobectomy. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 1082-1084.	0.9	0
130	Comment on "Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review" <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 261-262.	1.1	5
131	Expression of LICAM in curettage or high LICAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 840-847.	6.4	26
132	Long-term prognosis of young breast cancer patients (≥ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017, 7, e017842.	1.9	11
133	Breast Cancer (Diagnosed) During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. , 2017, , 709-718.		0
134	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	7.0	80
135	Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 61-67.	2.5	9
136	Ovarian cancer in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 108-117.	2.8	41
137	Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners. <i>Psycho-Oncology</i> , 2017, 26, 1215-1221.	2.3	31
138	Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. <i>PLoS ONE</i> , 2017, 12, e0182223.	2.5	7
139	Your contribution to Gynecological Surgery now freely available to the global scientific community. <i>Gynecological Surgery</i> , 2017, 14, .	0.9	0
140	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5613-TPS5613.	1.6	4
141	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1525.	4.1	3
142	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 2-30.	2.5	515
143	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over	0,9	5
144	External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 83-88.	1.4	4

#	ARTICLE	IF	CITATIONS
145	Characteristics and prognosis of patients with early-stage endometrial cancer who refuse adjuvant radiotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 428-433.	1.4	8
146	Mesonephric (Wolffian) Pseudoendometrioid Carcinoma of the Broad Ligament, Arising From a Papillary Cystadenoma. <i>International Journal of Surgical Pathology</i> , 2016, 24, 635-639.	0.8	5
147	Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. <i>European Journal of Cancer</i> , 2016, 61, 52-60.	2.8	27
148	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	21.4	77
149	Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. <i>British Journal of Radiology</i> , 2016, 89, 20160468.	2.2	18
150	Recurrent <i>PPP2R1A</i> Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. <i>Cancer Research</i> , 2016, 76, 5719-5731.	0.9	89
151	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. <i>British Journal of Cancer</i> , 2016, 115, 716-724.	6.4	76
152	Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. <i>European Journal of Cancer</i> , 2016, 65, 185-191.	2.8	35
153	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	2.5	64
154	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. <i>Nature</i> , 2016, 537, 63-68.	27.8	521
155	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. <i>Endoscopy</i> , 2016, 48, 1016-1022.	1.8	10
156	Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1399-1406.	2.5	22
157	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 77-91.	3.1	62
158	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-508.	1.6	78
159	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 319-330.	2.5	25
160	Melanoma addiction to the long non-coding RNA SAMMSON. <i>Nature</i> , 2016, 531, 518-522.	27.8	488
161	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. <i>New England Journal of Medicine</i> , 2016, 374, 692-693.	27.0	10
162	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. <i>Lancet Oncology</i> , 2016, 17, 273-274.	10.7	9

#	ARTICLE	IF	CITATIONS
163	Effects of prenatal exposure to cancer treatment on neurocognitive development, a review. <i>NeuroToxicology</i> , 2016, 54, 11-21.	3.0	6
164	Difficulties with diagnosis of malignancies in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2016, 33, 19-32.	2.8	50
165	Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. <i>Anticancer Research</i> , 2016, 36, 5381-5384.	1.1	6
166	Neonatal and Long-Term Consequences of In Utero Exposure to Systemic Anticancer Therapy. , 2016, , 97-110.		1
167	Abstract P6-09-12: Breast cancer characteristics and the levonorgestrel intrauterine device. A monocentric retrospective study. , 2016, , .		0
168	Abstract P6-10-06: The impact of body mass index on age at breast cancer diagnosis and breast cancer phenotype. , 2016, , .		0
169	705 Whole-body diffusion-weighted MRI for staging of women with cancer during pregnancy: A pilot study. <i>European Journal of Cancer</i> , 2015, 51, S129.	2.8	0
170	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. <i>Scientific Reports</i> , 2015, 5, 17369.	3.3	35
171	3205 Obstetrical complications and neonatal outcome in patients diagnosed with acute myeloid and acute lymphoblastic leukemia during pregnancy: Results from the International Network on Cancer, Infertility and Pregnancy (INCIP) study. <i>European Journal of Cancer</i> , 2015, 51, S650.	2.8	0
172	In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer. <i>Journal of Immunotherapy</i> , 2015, 38, 239-249.	2.4	8
173	Potential Therapeutic Targets in Uterine Sarcomas. <i>Sarcoma</i> , 2015, 2015, 1-14.	1.3	34
174	Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. <i>Sarcoma</i> , 2015, 2015, 1-14.	1.3	22
175	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. <i>JAMA Oncology</i> , 2015, 1, 814.	7.1	180
176	Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. <i>Gynecologic Oncology</i> , 2015, 138, 299-303.	1.4	50
177	Optimal Staging of Lymphoma during Pregnancy is Crucial. <i>Women's Health</i> , 2015, 11, 101-102.	1.5	1
178	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S96-104.	2.3	70
179	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.6	167
180	Contraception is as important as fertility preservation in young women with cancer. <i>Lancet</i> , The, 2015, 385, 508.	13.7	11

#	ARTICLE	IF	CITATIONS
181	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. <i>Lancet Haematology</i> , 2015, 2, e55-e65.	4.6	115
182	The immune system in the normal endometrium and implications for endometrial cancer development. <i>Journal of Reproductive Immunology</i> , 2015, 109, 7-16.	1.9	76
183	Sexual Functioning in Women After Surgical Treatment for Endometrial Cancer: A Prospective Controlled Study. <i>Journal of Sexual Medicine</i> , 2015, 12, 198-209.	0.6	44
184	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402.	6.3	229
185	Breast Cancer Diagnosed During Pregnancy. <i>JAMA Oncology</i> , 2015, 1, 1145.	7.1	169
186	Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 830-831.	1.3	2
187	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. <i>Gynecologic Oncology</i> , 2015, 139, 118-126.	1.4	52
188	DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. <i>British Journal of Cancer</i> , 2015, 112, 1656-1664.	6.4	24
189	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. <i>Gynecologic Oncology</i> , 2015, 138, 165-173.	1.4	26
190	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. <i>Modern Pathology</i> , 2015, 28, 1001-1010.	5.5	60
191	Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 845-857.	2.8	30
192	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 415-422.	2.8	34
193	Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. <i>Human Genetics</i> , 2015, 134, 231-245.	3.8	34
194	Morcellation of presumed benign uterine tumors: abandon the technique or patient triage?. <i>Gynecological Surgery</i> , 2015, 12, 1-2.	0.9	0
195	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2.	2.4	33
196	Management of cancer in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 741-753.	2.8	63
197	Microsatellite Instable and Microsatellite Stable Primary Endometrial Carcinoma Cells and Their Subcutaneous and Orthotopic Xenografts Recapitulate the Characteristics of the Corresponding Primary Tumor. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 363-371.	2.5	6
198	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. <i>New England Journal of Medicine</i> , 2015, 373, 1824-1834.	27.0	283

#	ARTICLE	IF	CITATIONS
199	Morcellation of uterine leiomyomas: a plea for patient triage. <i>Lancet Oncology</i> , The, 2015, 16, 1454-1456.	10.7	22
200	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. <i>Gynecologic Oncology</i> , 2015, 138, 378-382.	1.4	5
201	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 851-861.	3.1	25
202	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. <i>Gynecologic Oncology</i> , 2015, 138, 278-284.	1.4	19
203	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	2.9	50
204	Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. <i>Journal of Clinical Investigation</i> , 2015, 126, 68-84.	8.2	138
205	Spontaneous Post-Transplant Disorders in NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. <i>PLoS ONE</i> , 2015, 10, e0124974.	2.5	23
206	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014, 13, 223.	19.2	88
207	Management of Gynecological Cancers During Pregnancy. <i>Current Oncology Reports</i> , 2014, 16, 415.	4.0	24
208	Longitudinal Assessment of Chemotherapy-Induced Alterations in Brain Activation During Multitasking and Its Relation With Cognitive Complaints. <i>Journal of Clinical Oncology</i> , 2014, 32, 2031-2038.	1.6	66
209	Dendritic cell immunotherapy in uterine cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1822-1827.	3.3	6
210	Identification of a novel, recurrent <i>MBTD1-Xorf67</i> fusion in low-grade endometrial stromal sarcoma. <i>International Journal of Cancer</i> , 2014, 134, 1112-1122.	5.1	117
211	15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft models. <i>European Journal of Cancer</i> , 2014, 50, 11.	2.8	0
212	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	1.4	38
213	FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA. <i>Histopathology</i> , 2014, 65, 371-388.	2.9	3
214	Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1653-1665.	2.4	7
215	Locoregional treatment of breast cancer during pregnancy. <i>Gynecological Surgery</i> , 2014, 11, 279-284.	0.9	48
216	Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 394-403.	2.5	198

#	ARTICLE	IF	CITATIONS
217	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Endometrial Stromal Sarcoma. International Journal of Gynecological Cancer, 2014, 24, S67-S72.	2.5	75
218	Synchronous Ovarian and Endometrial Cancer – an International Multicenter Case-Control Study. International Journal of Gynecological Cancer, 2014, 24, 54-60.	2.5	52
219	Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment. International Journal of Gynecological Cancer, 2014, 24, 468-477.	2.5	30
220	Growth Differentiation Factor-15 as Biomarker in Uterine Sarcomas. International Journal of Gynecological Cancer, 2014, 24, 252-259.	2.5	21
221	Breastfeeding a child on treatment for childhood cancer. Journal of Oncology Pharmacy Practice, 2014, 20, 237-238.	0.9	0
222	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Breast, 2014, 23, 453-459.	2.2	15
223	Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. European Radiology, 2014, 24, 889-901.	4.5	189
224	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer, 2014, 50, 1462-1471.	2.8	54
225	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	2.2	135
226	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Human Pathology, 2014, 45, 522-532.	2.0	36
227	Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology, 2014, 25, 2059-2065.	1.2	60
228	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	9.4	1,341
229	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. Journal of Translational Medicine, 2014, 12, 179.	4.4	14
230	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 545-557.	4.2	102
231	Conditioning of the abdominal cavity reduces tumor implantation in a laparoscopic mouse model. Surgery Today, 2014, 44, 1328-1335.	1.5	17
232	Strategies for fertility preservation in young early breast cancer patients. Breast, 2014, 23, 503-510.	2.2	42
233	Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: A prospective controlled study. Breast, 2014, 23, 629-636.	2.2	116
234	Cancer during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 443-446.	2.8	20

#	ARTICLE	IF	CITATIONS
235	Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 255-256.	1.6	3
236	Psychologic, Relational, and Sexual Functioning in Women After Surgical Treatment of Vulvar Malignancy: A Prospective Controlled Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 372-380.	2.5	32
237	Long-Term Sexual Functioning in Women After Surgical Treatment of Cervical Cancer Stages IA to IB: A Prospective Controlled Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1527-1534.	2.5	34
238	Neoadjuvant chemotherapy for patients with breast cancer during pregnancy (BCP).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1071-1071.	1.6	4
239	Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. <i>ELife</i> , 2014, 3, e02725.	6.0	71
240	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5621-TPS5621.	1.6	0
241	Non-Invasive Detection of Genomic Imbalances in Hodgkin/Reed-Sternberg Cells in Early and Advanced Stage Hodgkin Lymphoma By Sequencing of Circulating Cell-Free DNA. <i>Blood</i> , 2014, 124, LBA-4-LBA-4.	1.4	0
242	Tongue cancers during pregnancy: Case reports and review of literature. <i>Head and Neck</i> , 2013, 35, E102-8.	2.0	12
243	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. <i>European Journal of Cancer</i> , 2013, 49, 3431-3441.	2.8	123
244	Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. <i>Gynecologic Oncology</i> , 2013, 130, 192-199.	1.4	50
245	Evaluation of the quality of the management of cancer of the corpus uteri " Selection of relevant quality indicators and implementation in Belgium. <i>Gynecologic Oncology</i> , 2013, 131, 512-519.	1.4	15
246	Cancer in pregnancy: a survey of current clinical practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 167, 18-23.	1.1	51
247	Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. <i>European Journal of Cancer</i> , 2013, 49, 1600-1608.	2.8	57
248	Effects of Fetal Exposure to Maternal Chemotherapy. <i>Paediatric Drugs</i> , 2013, 15, 329-334.	3.1	22
249	Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3127-3132.	1.6	25
250	The functional neuroanatomy of multitasking: Combining dual tasking with a short term memory task. <i>Neuropsychologia</i> , 2013, 51, 2251-2260.	1.6	42
251	Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. <i>Gynecologic Oncology</i> , 2013, 128, 6-11.	1.4	105
252	The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. <i>Gynecologic Oncology</i> , 2013, 128, 34-37.	1.4	9

#	ARTICLE	IF	CITATIONS
253	Myocardial function in children after fetal chemotherapy exposure. A tissue Doppler and myocardial deformation imaging study. <i>European Journal of Pediatrics</i> , 2013, 172, 163-170.	2.7	25
254	Is chemotherapy during the first trimester of pregnancy really safe?. <i>International Journal of Cancer</i> , 2013, 132, 1728-1728.	5.1	6
255	Lung cancer in pregnancy: Report of nine cases from an international collaborative study. <i>Lung Cancer</i> , 2013, 82, 499-505.	2.0	107
256	PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 694-700.	1.4	54
257	High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 327-334.	1.4	68
258	A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. <i>European Journal of Cancer</i> , 2013, 49, 625-632.	2.8	29
259	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	2.5	22
260	L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1142-1150.	6.3	185
261	Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2532-2539.	1.6	261
262	Fetal Rat Hearts Do Not Display Acute Cardiotoxicity in Response to Maternal Doxorubicin Treatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 362-369.	2.5	10
263	Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 211-219.	3.2	33
264	Genetic changes in nonepithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 871-882.	2.4	16
265	Trastuzumab, lapatinib and bevacizumab during pregnancy. <i>Breast Cancer Management</i> , 2013, 2, 5-7.	0.2	1
266	Increased expression of placental growth factor in high-grade endometrial carcinoma. <i>Oncology Reports</i> , 2013, 29, 413-418.	2.6	11
267	Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.. , 2013, , .		1
268	Abstract P1-13-08: Arthralgia and changes in serum levels of IGF-I, its binding protein and estrogen in breast cancer patients on endocrine agents. , 2013, , .		0
269	Abstract PD2-3: High body mass index (BMI) and worse response to neoadjuvant chemotherapy (NACT) by breast cancer phenotype: Own data and external validation on German breast group (GBG) patients. , 2013, , .		0
270	Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. <i>Anticancer Research</i> , 2013, 33, 3855-9.	1.1	36

#	ARTICLE	IF	CITATIONS
271	Wilms' Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. <i>Anticancer Research</i> , 2013, 33, 5495-500.	1.1	37
272	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	1.2	46
273	Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. <i>Annals of Oncology</i> , 2012, 23, 1449-1454.	1.2	49
274	Chemotherapy during pregnancy. <i>Current Opinion in Oncology</i> , 2012, 24, 580-586.	2.4	39
275	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 929-934.	7.1	239
276	Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation With Impaired Cognitive Functioning. <i>Journal of Clinical Oncology</i> , 2012, 30, 274-281.	1.6	334
277	Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 617-622.	2.5	12
278	Being Pregnant and Diagnosed with Breast Cancer. <i>Breast Care</i> , 2012, 7, 204-209.	1.4	11
279	ESGO Statement on the Role of CA125 Measurement in Follow-Up of Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 175-175.	2.5	6
280	EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 875-880.	2.5	15
281	Pelvic Exenterations for Gynecological Malignancies. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 889-896.	2.5	42
282	Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced, Recurrent, or Metastatic Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 865-868.	2.5	33
283	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 641-653.	3.7	265
284	Breast cancer in pregnancy. <i>Lancet</i> , The, 2012, 379, 570-579.	13.7	216
285	Treatment of breast cancer during pregnancy: an observational study. <i>Lancet Oncology</i> , The, 2012, 13, 887-896.	10.7	224
286	Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2012, 13, 154-162.	10.7	141
287	Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. <i>Lancet Oncology</i> , The, 2012, 13, 256-264.	10.7	237
288	796 Establishment of Primary Endometrial Carcinoma Cell Cultures as a Preclinical Tool for Drug Screening – Methods and Characterization. <i>European Journal of Cancer</i> , 2012, 48, S189-S190.	2.8	1

#	ARTICLE	IF	CITATIONS
289	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S110-7.	2.3	149
290	Clinically oriented three-step strategy for assessment of adnexal pathology. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 582-591.	1.7	61
291	Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide. <i>Gynecologic Oncology</i> , 2012, 127, 47-50.	1.4	8
292	1090 Tumor-associated Antigen Validation in Uterine Tumors. <i>European Journal of Cancer</i> , 2012, 48, S262.	2.8	0
293	IN23 Breast cancer during pregnancy: the obstetrician/paediatric perspective. <i>Breast</i> , 2012, 21, S8.	2.2	0
294	Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. <i>European Journal of Cancer</i> , 2012, 48, 1649-1656.	2.8	104
295	Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. <i>European Journal of Cancer</i> , 2012, 48, 1332-1340.	2.8	18
296	Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. <i>BMC Medicine</i> , 2012, 10, 86.	5.5	103
297	Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 1465-1468.	2.8	30
298	Use of general anesthesia and sentinel node procedure during pregnancy. <i>Journal of Surgical Oncology</i> , 2012, 106, 1008-1008.	1.7	4
299	Effects of chemotherapy during pregnancy on the maternal and fetal heart. <i>Prenatal Diagnosis</i> , 2012, 32, 614-619.	2.3	15
300	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	2.5	32
301	Screening for uterine tumours. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 257-266.	2.8	72
302	Sexual, Psychological, and Relational Functioning in Women After Surgical Treatment for Vulvar Malignancy: A Literature Review. <i>Journal of Sexual Medicine</i> , 2012, 9, 361-371.	0.6	71
303	Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. <i>Gynecologic Oncology</i> , 2012, 125, 103-108.	1.4	50
304	Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?. <i>Gynecologic Oncology</i> , 2012, 124, 1-2.	1.4	27
305	Role of Neoadjuvant Chemotherapy in the Management of Stage III-IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 407-416.	2.5	33
306	Progesterone Inhibits Epithelial-to-Mesenchymal Transition in Endometrial Cancer. <i>PLoS ONE</i> , 2012, 7, e30840.	2.5	66

#	ARTICLE	IF	CITATIONS
307	Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. , 2012, , .		0
308	Abstract P6-05-05: Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis. , 2012, , .		0
309	Abstract P6-07-29: Independent prognostic value of age depends on breast cancer subtype. , 2012, , .		0
310	Abstract P2-10-12: How well predict the 2011 St Gallen early breast cancer surrogate phenotypes metastatic survival?. , 2012, , .		0
311	Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: An analysis of 163 patients. <i>European Journal of Cancer</i> , 2011, 47, 191-198.	2.8	11
312	Use of chemotherapy during pregnancy in the treatment of ovarian malignancies. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 156, 237.	1.1	1
313	Cognitive and Cardiac Outcome After Prenatal Exposure to Chemotherapy in Children 18 Months or Older. <i>European Journal of Cancer</i> , 2011, 47, 8.	2.8	2
314	Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. <i>European Journal of Cancer</i> , 2011, 47, S88-S92.	2.8	106
315	298 INVITED Management Aimed at Fertility Preservation. <i>European Journal of Cancer</i> , 2011, 47, S68.	2.8	0
316	Should we screen for endometrial cancer?. <i>Lancet Oncology</i> , The, 2011, 12, 4-5.	10.7	20
317	Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting. , 2011, , 209-227.		1
318	Wilms Tumor Gene 1(WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 302-308.	2.5	24
319	Expression of ERCC1, p53, and Class III β -Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1071-1077.	2.5	10
320	Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 316-322.	2.5	22
321	Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. <i>Menopause</i> , 2011, 18, 224-229.	2.0	2
322	<i>KIT</i> Gene in Endometrial Carcinoma: An Immunohistochemical and Mutational Analysis. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 203-205.	2.5	6
323	The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 332-336.	2.5	21
324	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141

#	ARTICLE	IF	CITATIONS
325	HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. <i>British Journal of Cancer</i> , 2011, 104, 863-870.	6.4	270
326	Polypoid endometriosis of the bladder during pregnancy mimicking urachal carcinoma. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 475-478.	1.7	24
327	Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 429-435.	2.5	26
328	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1347-1353.	2.3	8
329	Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. <i>Human Brain Mapping</i> , 2011, 32, 480-493.	3.6	228
330	Substantial Variation in Transplacental Transfer of Chemotherapeutic Agents in a Mouse Model. <i>Reproductive Sciences</i> , 2011, 18, 57-63.	2.5	48
331	Gynecological Cancer During Pregnancy. , 2011, , 77-96.		0
332	Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 588-594.	1.2	25
333	Psycho-Oncology: Structure and Profiles of European Centers Treating Patients With Gynecological Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1520-1524.	2.5	3
334	Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3368-3377.	7.0	113
335	Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4076-4078.	1.6	59
336	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. <i>Carcinogenesis</i> , 2011, 32, 1862-1866.	2.8	5
337	Progesterone receptor gene variants and risk of endometrial cancer. <i>Carcinogenesis</i> , 2011, 32, 331-335.	2.8	22
338	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e19642.	2.5	5
339	Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	9
340	P2-17-09: A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen.. , 2011, , .		1
341	P4-09-07: Breast Cancer Outcome by Combined Immunohistochemical ER/PR/HER2 Receptor Phenotype.. , 2011, , .		0
342	P1-08-20: Parity Interferes with the Effect of Age at Diagnosis on the Frequency Breast Cancers Are Triple-Negative.. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
343	Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. <i>Anticancer Research</i> , 2011, 31, 2367-71.	1.1	18
344	The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 542-551.	2.5	9
345	The Use of Lymph Vessel Markers to Predict Endometrial Cancer Outcome. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 363-367.	2.5	13
346	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1338-1345.	2.8	101
347	Gynaecologic cancer complicating pregnancy: An overview. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2010, 24, 61-79.	2.8	85
348	Diaphragmatic surgery during primary debulking in 89 patients with stage IIIBâ€“IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 489-496.	1.4	31
349	The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. <i>Gynecologic Oncology</i> , 2010, 117, 358-365.	1.4	53
350	The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. <i>Gynecologic Oncology</i> , 2010, 118, 64-68.	1.4	5
351	What is the role of neoadjuvant chemotherapy in advanced endometrial cancer?. <i>Gynecologic Oncology</i> , 2010, 119, 601.	1.4	2
352	Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?. <i>Gynecologic Oncology</i> , 2010, 119, 1-2.	1.4	30
353	Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. <i>Gynecologic Oncology</i> , 2010, 119, 594-600.	1.4	82
354	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	21.4	235
355	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
356	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2106-2109.	2.5	24
357	Reply to H.A. Azim Jr et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e304-e304.	1.6	2
358	Primary Retroperitoneal Mucinous Cystadenocarcinoma: A Case Report and Review of the Literature. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 186-191.	1.6	15
359	Clinical Recommendation on Fertility Preservation in Borderline Ovarian Neoplasm: Ovarian Stimulation and Oocyte Retrieval after Conservative Surgery. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 160-165.	1.6	39
360	Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 4129-4134.	1.6	51

#	ARTICLE	IF	CITATIONS
361	Revised FIGO staging for endometrial cancer. Southern African Journal of Gynaecological Oncology, 2010, 2, 40-41.	0.3	0
362	LATE RECURRENT OVARIAN CARCINOMA METASTATIC TO THE THORACIC WALL. Acta Clinica Belgica, 2010, 65, 354-356.	1.2	11
363	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	2.8	238
364	Laparoscopic hysterectomy for early endometrial cancer. Lancet Oncology, The, 2010, 11, 707-708.	10.7	6
365	Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine, 2010, 363, 943-953.	27.0	2,066
366	High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. Journal of Medical Case Reports, 2010, 4, 243.	0.8	8
367	Cancer During Pregnancy: An Analysis of 215 Patients Emphasizing the Obstetrical and the Neonatal Outcomes. Journal of Clinical Oncology, 2010, 28, 683-689.	1.6	377
368	Fertility preserving management in gynecologic cancer patients: the need for centralization. International Journal of Gynecological Cancer, 2010, 20, 1613-9.	2.5	24
369	Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. International Journal of Gynecological Cancer, 2010, 20, 1456-64.	2.5	75
370	Abstract S6-2: 313 Patients with Breast Cancer during Pregnancy " Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03). , 2010, , .		12
371	Abstract P4-08-09: The Prognostic Importance of "Detection Mode" and "Palpability" in Primary Operable Grade 2 Breast Cancers. , 2010, , .		0
372	Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Research, 2010, 30, 3709-14.	1.1	20
373	Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?. British Journal of Cancer, 2009, 101, 244-249.	6.4	80
374	Feasibility of Ultrasound-guided Percutaneous Samplings in the Pregnant Baboon: A Model for Studies on Transplacental Transport. Reproductive Sciences, 2009, 16, 280-285.	2.5	8
375	Is It Safe to Treat Endometrial Carcinoma Endoscopically?. Journal of Clinical Oncology, 2009, 27, 5305-5307.	1.6	9
376	Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer. Gynecologic and Obstetric Investigation, 2009, 67, 46-48.	1.6	10
377	Reproduction Rates After Cytotoxic Therapy. Journal of Clinical Oncology, 2009, 27, e118-e119.	1.6	4
378	Residual tumor after neoadjuvant chemotherapy and interval debulking surgery for advanced endometrial cancer. Gynecologic Oncology, 2009, 114, 370.	1.4	2

#	ARTICLE	IF	CITATIONS
379	Application of proteomics in ovarian cancer: Which sample should be used?. <i>Gynecologic Oncology</i> , 2009, 115, 497-503.	1.4	13
380	0090 Axillary staging of breast cancer with the sentinel lymph node (SLN) procedure in over a thousand patients with early breast cancer. <i>Breast</i> , 2009, 18, S41.	2.2	0
381	0139 Why 28% of ER-negative/PR-negative breast cancer (BC) patients did not get chemotherapy (CT). <i>Breast</i> , 2009, 18, S53.	2.2	0
382	0192 Does the stellate ganglion block reduce severe hot flushes and sleep disturbances in breast cancer patients?. <i>Breast</i> , 2009, 18, S67.	2.2	0
383	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 349-358.	2.5	18
384	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 181-187.	2.5	76
385	Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 103-112.	2.5	26
386	Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 531-538.	2.5	14
387	Wilms' tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours. <i>Histopathology</i> , 2009, 54, 384-387.	2.9	3
388	Sonographic biometrical normograms and estimation of fetal weight in the baboon (<i>Papio</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 0.6	0.6	5
389	Hyperreactio luteinalis in a spontaneously conceived singleton pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 33, 371-373.	1.7	39
390	Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot study. <i>Fertility and Sterility</i> , 2009, 91, 1441-1444.	1.0	8
391	Vinblastine and doxorubicin administration to pregnant mice affects brain development and behaviour in the offspring. <i>NeuroToxicology</i> , 2009, 30, 647-657.	3.0	19
392	Screening for ovarian carcinoma: not quite there yet. <i>Lancet Oncology</i> , The, 2009, 10, 308-309.	10.7	11
393	Clinical management of uterine sarcomas. <i>Lancet Oncology</i> , The, 2009, 10, 1188-1198.	10.7	374
394	Lymphadenectomy in endometrial cancer. <i>Lancet</i> , The, 2009, 373, 1169-1170.	18.7	17
395	Gynecologic Cancers in Pregnancy. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S1-S12.	2.5	103
396	Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1505-1510.	2.5	7

#	ARTICLE	IF	CITATIONS
397	Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1147-1151.	2.5	21
398	Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1501-1504.	2.5	7
399	Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 245-248.	2.5	20
400	Role of Diaphragmatic Surgery in 69 Patients With Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 481-481.	2.5	11
401	Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 79-86.	2.5	16
402	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 153-159.	2.5	11
403	Gynecologic oncology in pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 187-195.	4.4	26
404	Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 250-253.	2.8	11
405	Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 783-787.	2.8	70
406	Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 363-368.	2.5	35
407	Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2/IIIb. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 723-729.	2.5	40
408	Timing of debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 11-19.	2.5	79
409	Classification of radical hysterectomy adopted by the Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1136-1138.	2.5	38
410	Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. <i>BMC Cancer</i> , 2008, 8, 18.	2.6	13
411	Wilms' tumor gene 1 (WT1) in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2008, 111, 502-508.	1.4	27
412	The Addition of 4% Oxygen to the CO2 Pneumoperitoneum Does Not Decrease Dramatically Port Site Metastases. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 700-703.	0.6	8
413	Complete hydatidiform mole with co-existing healthy fetus: A case report. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 341-344.	1.5	9
414	Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. <i>Oncologist</i> , 2008, 13, 410-414.	3.7	23

#	ARTICLE	IF	CITATIONS
415	Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor. <i>Breast Care</i> , 2008, 3, 8-8.	1.4	4
416	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFACT. <i>Journal of Clinical Oncology</i> , 2008, 26, 1664-1670.	1.6	460
417	Does Estrogen Receptor-Negative/Progesterone Receptor-Positive Breast Carcinoma Exist?. <i>Journal of Clinical Oncology</i> , 2008, 26, 335-336.	1.6	91
418	Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB. <i>Journal of Clinical Oncology</i> , 2008, 26, 5654-5655.	1.6	12
419	In Early-Stage Breast Cancer, the Estrogen Receptor Interacts With Correlation Between Human Epidermal Growth Factor Receptor 2 Status and Age at Diagnosis, Tumor Grade, and Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2008, 26, 1768-1769.	1.6	4
420	INTRAVASCULAR LARGE B-CELL LYMPHOMA OF THE UTERUS PRESENTING AS FEVER OF UNKNOWN ORIGIN (FUO) AND REVEALED BY FDG-PET. <i>Acta Clinica Belgica</i> , 2007, 62, 187-190.	1.2	22
421	Treatment modalities in endometrial cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 479-485.	2.4	40
422	Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. <i>European Journal of Cancer</i> , 2007, 43, 1630-1637.	2.8	44
423	Improving outcome in the first-line management of advanced ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-28.	2.2	3
424	Management of Borderline Ovarian Neoplasms. <i>Journal of Clinical Oncology</i> , 2007, 25, 2928-2937.	1.6	174
425	Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. <i>British Journal of Cancer</i> , 2007, 97, 1194-1199.	6.4	136
426	Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 83-87.	2.5	14
427	Dormant foci of endometrial stromal sarcoma as an intermediate between an indolent and aggressive growth. <i>Gynecologic Oncology</i> , 2007, 105, 278-279.	1.4	0
428	The 'Leuven' dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 106, 354-361.	1.4	37
429	Chemotherapy for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, S113-S118.	1.4	47
430	P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive. <i>Breast</i> , 2007, 16, S27.	2.2	0
431	Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 29, 496-504.	1.7	36
432	A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 29, 674-679.	1.7	43

#	ARTICLE	IF	CITATIONS
433	Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 248.e1-248.e8.	1.3	87
434	Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 87-91.	2.5	111
435	Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 127-133.	2.5	19
436	Laparoscopy and peritoneal tuberculosis. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 95, 58-59.	2.3	1
437	Urachal carcinoma during pregnancy. <i>Urology</i> , 2006, 67, 1290.e19-1290.e21.	1.0	5
438	Pseudomyxoma Peritonei Associated With a Mucinous Ovarian Tumor Arising From a Mature Cystic Teratoma. A Case Report. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 340-343.	1.4	21
439	The management of borderline tumours of the ovary. <i>Current Opinion in Oncology</i> , 2006, 18, 488-493.	2.4	32
440	Aromatase Inhibitors in Premenopausal Women: The Need for Proper Contraceptive Counseling. <i>Breast Journal</i> , 2006, 12, 507-508.	1.0	5
441	Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 905-908.	2.5	93
442	Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 183-188.	2.5	28
443	Predicting the clinical behavior of ovarian cancer from gene expression profiles. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 147-151.	2.5	23
444	Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 273-277.	2.5	32
445	Second case of uterine mesonephric adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1450-1454.	2.5	20
446	Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1885-1893.	2.5	5
447	Methodology in plasma proteomic pattern experiments. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1951-1952.	2.5	0
448	Ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 159-179.	4.4	186
449	New models to predict depth of infiltration in endometrial carcinoma based on transvaginal sonography. <i>Ultrasound in Obstetrics and Gynecology</i> , 2006, 27, 664-671.	1.7	42
450	Transition of endometrial stromal sarcoma into high-grade sarcoma. <i>Gynecologic Oncology</i> , 2006, 103, 1137-1140.	1.4	45

#	ARTICLE	IF	CITATIONS
451	Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 415-417.	1.4	20
452	Pathology and physiopathology of adenomyosis. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 511-521.	2.8	283
453	Molecular profiling of platinum resistant ovarian cancer: Use of the model in clinical practice. <i>International Journal of Cancer</i> , 2006, 119, 1511-1511.	5.1	1
454	In Utero Exposure to Chemotherapy: Effect on Cardiac and Neurologic Outcome. <i>Journal of Clinical Oncology</i> , 2006, 24, e16-e17.	1.6	35
455	Progesterone Receptor in Estrogen Receptor Positive Breast Cancer: The Association Between HER-2 and Lymph Node Involvement Is Age Related. <i>Journal of Clinical Oncology</i> , 2006, 24, 2595-2595.	1.6	6
456	Fertility Preservation in (Breast) Cancer Patients: Is it Safe?. <i>Journal of Clinical Oncology</i> , 2006, 24, 5335-5336.	1.6	5
457	Ultrasound features of different histopathological subtypes of borderline ovarian tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2005, 26, 644-650.	1.7	56
458	Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 776-779.	2.5	113
459	Role of adnexectomy in the surgical treatment of cervical adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 984.	2.5	0
460	Role of cyclin-dependent kinase p27 in uterine carcinosarcomas. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 986-987.	2.5	2
461	Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 1210-1212.	2.5	30
462	Cervical neoplasia during pregnancy: Diagnosis, management and prognosis. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2005, 19, 611-630.	2.8	94
463	The rationale for comprehensive surgical staging in endometrial carcinosarcoma. <i>Gynecologic Oncology</i> , 2005, 99, 521-522.	1.4	15
464	Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 98, 274-280.	1.4	142
465	Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. <i>Gynecologic Oncology</i> , 2005, 98, 523-524.	1.4	11
466	CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. <i>Gynecologic Oncology</i> , 2005, 99, 493-496.	1.4	11
467	Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 81-87.	2.5	56
468	Different Subtypes of Uterine Sarcoma Require a Separate Therapeutic Approach. <i>Women's Health</i> , 2005, 1, 375-383.	1.5	0

#	ARTICLE	IF	CITATIONS
469	Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. <i>Annals of Oncology</i> , 2005, 16, 1755-1761.	1.2	39
470	Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. <i>Journal of Clinical Pathology</i> , 2005, 58, 611-616.	2.0	141
471	Endometrial cancer. <i>Lancet, The</i> , 2005, 366, 491-505.	13.7	1,368
472	Lymphoblastic lymphoma presenting as bilateral gigantomastia in pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2005, 91, 252-253.	2.3	14
473	Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristone. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 120, 233-235.	1.1	8
474	A possible role of the cytochrome P450c17 β gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 234-239.	2.8	12
475	Immunohistochemical expression of CD10 antigen in uterine adenosarcoma. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 1118-1121.	2.5	41
476	Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2004, 93, 272-273.	1.4	4
477	Letter to the Editor. <i>Gynecologic Oncology</i> , 2004, 94, 607.	1.4	1
478	Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. <i>Gynecologic Oncology</i> , 2004, 93, 680-685.	1.4	58
479	Response: The classification of a uterine sarcoma as "High-grade endometrial stromal sarcoma"™ should be abandoned. <i>Gynecologic Oncology</i> , 2004, 95, 412-413.	1.4	46
480	ERBB-2 gene overexpression and amplification in uterine sarcomas. <i>Gynecologic Oncology</i> , 2004, 95, 583-587.	1.4	54
481	Endometriosis and the development of malignant tumours of the pelvis. A review of literature. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2004, 18, 349-371.	2.8	257
482	The progesterone receptor has a prognostic value in oestrogen receptor negative breast cancers. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 103-104.	2.2	2
483	Women under age 50 with an ER-positive breast cancer are more likely to have positive lymph nodes if PR is not expressed. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 179.	2.2	0
484	Immunohistochemical determination of hormone receptors in uterine adenosarcomas. <i>Gynecologic Oncology</i> , 2003, 88, 463-464.	1.4	12
485	Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature. <i>Gynecologic Oncology</i> , 2003, 88, 459-462.	1.4	24
486	Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 88, 266-269.	1.4	99

#	ARTICLE	IF	CITATIONS
487	The diagnostic problem of endometrial stromal sarcoma: report on six cases. <i>Gynecologic Oncology</i> , 2003, 90, 37-43.	1.4	71
488	Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. <i>Gynecologic Oncology</i> , 2003, 90, 372-377.	1.4	34
489	Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. <i>Gynecologic Oncology</i> , 2003, 91, 265-271.	1.4	47
490	2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. <i>Gynecologic Oncology</i> , 2003, 91, 299-308.	1.4	12
491	Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 522-527.	2.5	241
492	Bifunctional pathway of uterine carcinosarcomas. <i>Human Pathology</i> , 2003, 34, 299.	2.0	5
493	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. <i>Journal of the Society for Gynecologic Investigation</i> , 2003, 10, 105-109.	1.7	16
494	PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 258.	1.3	7
495	Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 22-26.	2.5	78
496	To the Editor. <i>Gynecologic Oncology</i> , 2002, 84, 537.	1.4	16
497	PTEN Mutations in Uterine Sarcomas. <i>Gynecologic Oncology</i> , 2002, 85, 165-169.	1.4	45
498	Is weight of breast associated with hormone receptor expression in postmenopausal invasive breast cancer?. <i>European Journal of Cancer</i> , 2002, 38, S112.	2.8	0
499	The misoprostol third stage study: a randomised controlled comparison between orally administered misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 338.	0.9	4
500	Uterine Carcinosarcoma With Melanocytic Differentiation. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 186-190.	1.4	22
501	Microsatellite instability in uterine sarcomas. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 218-223.	2.5	35
502	Cumulative dosage effect of aRAD5111/HMGA2 fusion and RAD5111 loss in a case of pseudo-Meigs' syndrome. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 324-329.	2.8	12
503	Pseudo-Meigs' Syndrome Caused by a Hydropic Degenerating Uterine Leiomyoma with Elevated CA 125. <i>Gynecologic Oncology</i> , 2001, 83, 153-157.	1.4	55
504	The misoprostol third stage study: a randomised controlled comparison between orally administered misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 338-338.	2.3	7

#	ARTICLE	IF	CITATIONS
505	Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 1066-1070.	2.3	61
506	Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound in Obstetrics and Gynecology, 1999, 13, 11-16.	1.7	216
507	Gastrostomy Using a "Gastrofix" as an Alternative for Nasogastric Tubes in Ovarian Cancer Surgery. Gynecologic Oncology, 1998, 71, 348-351.	1.4	4
508	Hepatic necrosis and haemorrhage in pregnant patients with antiphospholipid antibodies. Lupus, 1997, 6, 552-555.	1.6	25
509	Liver involvement in HELLP syndrome: CT and MRI findings in two patients. European Radiology, 1995, 5, 331-334.	4.5	4
510	AIF4-induced inhibition of the ATPase activity, the Ca ²⁺ -transport activity and the phosphoprotein-intermediate formation of plasma-membrane and endo(sarco)plasmic-reticulum Ca ²⁺ -transport ATPases in different tissues. Evidence for a tissue-dependent functional difference. Biochemical Journal, 1989, 261, 655-660.	3.7	29